Cited by

• Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide.

  Boccuzzi G, Tamagno E, Brignardello E, Di Monaco M, Aragno M, Danni O. Boccuzzi G, et al. J Cancer Res Clin Oncol. 1995;121(3):150-4. doi: 10.1007/BF01198096. J Cancer Res Clin Oncol. 1995. PMID: 7713986 Free PMC article.
• Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors.

  Spinola PG, Marchetti B, Mérand Y, Bélanger A, Labrie F. Spinola PG, et al. Breast Cancer Res Treat. 1988 Dec;12(3):287-96. doi: 10.1007/BF01811241. Breast Cancer Res Treat. 1988. PMID: 3147727
• Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

  Labrie F, Li S, Bélanger A, Côté J, Mérand Y, Lepage M. Labrie F, et al. Breast Cancer Res Treat. 1993;26(3):253-65. doi: 10.1007/BF00665803. Breast Cancer Res Treat. 1993. PMID: 8251650
• The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region.

  Cato AC, Henderson D, Ponta H. Cato AC, et al. EMBO J. 1987 Feb;6(2):363-8. doi: 10.1002/j.1460-2075.1987.tb04763.x. EMBO J. 1987. PMID: 3034586 Free PMC article.
• Synthesis of 5α-androstane-17-spiro-δ-lactones with a 3-keto, 3-hydroxy, 3-spirocarbamate or 3-spiromorpholinone as inhibitors of 17β-hydroxysteroid dehydrogenases.

  Djigoué GB, Ngatcha BT, Roy J, Poirier D. Djigoué GB, et al. Molecules. 2013 Jan 11;18(1):914-33. doi: 10.3390/molecules18010914. Molecules. 2013. PMID: 23344201 Free PMC article.